All journal publications
Filters: author is Hammarlund-Udenaes [Clear All Filters]
- 2010
- 2009
Species differences in blood-brain barrier transport of three positron emission tomography radioligands with emphasis on P-glycoprotein transport,
Drug Metab Dispos, vol. 37, no. 3, pp. 635-43. DOI
- 2008
Pharmacokinetics of P-glycoprotein inhibition in the rat blood-brain barrier,
J Pharm Sci, vol. 97, no. 12, pp. 5386-400. DOI
Pharmacokinetics of P-glycoprotein inhibition in the rat blood-brain barrier,
J Pharm Sci, vol. 97, no. 12, pp. 5386-400. DOI
Pharmacokinetics of P-glycoprotein inhibition in the rat blood-brain barrier,
J Pharm Sci, vol. 97, no. 12, pp. 5386-400. DOI
On the rate and extent of drug delivery to the brain,
Pharm Res, vol. 25, no. 8, pp. 1737-50. DOI
On the rate and extent of drug delivery to the brain,
Pharm Res, vol. 25, no. 8, pp. 1737-50. DOI
On the rate and extent of drug delivery to the brain,
Pharm Res, vol. 25, no. 8, pp. 1737-50. DOI
- 2007
- 2006
Duration and degree of cyclosporin induced P-glycoprotein inhibition in the rat blood-brain barrier can be studied with PET,
Neuroimage, vol. 32, no. 3, pp. 1134-41. DOI
Duration and degree of cyclosporin induced P-glycoprotein inhibition in the rat blood-brain barrier can be studied with PET,
Neuroimage, vol. 32, no. 3, pp. 1134-41. DOI
Duration and degree of cyclosporin induced P-glycoprotein inhibition in the rat blood-brain barrier can be studied with PET,
Neuroimage, vol. 32, no. 3, pp. 1134-41. DOI
Predicting brain concentrations of drug using positron emission tomography and venous input: modeling of arterial-venous concentration differences,
Eur J Clin Pharmacol, vol. 62, no. 10, pp. 839-48. DOI
Predicting brain concentrations of drug using positron emission tomography and venous input: modeling of arterial-venous concentration differences,
Eur J Clin Pharmacol, vol. 62, no. 10, pp. 839-48. DOI
Predicting brain concentrations of drug using positron emission tomography and venous input: modeling of arterial-venous concentration differences,
Eur J Clin Pharmacol, vol. 62, no. 10, pp. 839-48. DOI
Pharmacokinetic consequences of active drug efflux at the blood-brain barrier,
Pharm Res, vol. 23, no. 4, pp. 705-17. DOI
Pharmacokinetic consequences of active drug efflux at the blood-brain barrier,
Pharm Res, vol. 23, no. 4, pp. 705-17. DOI
Pharmacokinetic consequences of active drug efflux at the blood-brain barrier,
Pharm Res, vol. 23, no. 4, pp. 705-17. DOI
- 1999
The role of P-glycoprotein in blood-brain barrier transport of morphine: transcortical microdialysis studies in mdr1a (-/-) and mdr1a (+/+) mice,
Br J Pharmacol, vol. 128, no. 3, pp. 563-8. DOI
- 1997
Drug equilibration across the blood-brain barrier--pharmacokinetic considerations based on the microdialysis method,
Pharm Res, vol. 14, no. 2, pp. 128-34.
- 0


